Mach7 Technologies Ltd. ( (TDMMF) ) has released its Q2 earnings. Here is a breakdown of the information Mach7 Technologies Ltd. presented to its investors.
Mach7 Technologies Ltd. is a company specializing in the development and commercialization of medical imaging and data management software solutions for global healthcare organizations.
In its latest half-year report ending December 31, 2024, Mach7 Technologies Ltd. showcased a significant improvement in its financial performance, reducing its net loss to AUD 1.87 million from AUD 4.63 million in the previous year. The company reported a 33% increase in revenue, reaching AUD 17.74 million, driven by a strategic shift towards subscription-based sales.
Key financial highlights include a 28% increase in annual recurring revenue (ARR) to AUD 12.65 million and a notable rise in software license revenue by 105% to AUD 3.54 million. Despite a 15% increase in operating expenses, the company achieved an adjusted EBITDA of AUD 0.81 million, marking a substantial turnaround from a negative EBITDA of AUD 1.57 million in the prior period.
Looking ahead, Mach7 Technologies remains optimistic about its growth prospects, supported by a robust sales pipeline and strategic positioning in both acute and non-acute care sectors. The company anticipates a 15-25% growth in contracted annual recurring revenue (CARR) and revenue for the fiscal year 2025, with operating expenses expected to grow at a slower pace than revenue.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com